About Acorda Therapeutics (NASDAQ:ACOR)
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$588.29 million
Price / Sales2.00
Cash Flow$1.78 per share
Price / Cash14.06
Book Value$11.12 per share
Price / Book2.25
Return on Equity-4.88%
Return on Assets-2.41%
Acorda Therapeutics (NASDAQ:ACOR) Frequently Asked Questions
What is Acorda Therapeutics' stock symbol?
Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."
How were Acorda Therapeutics' earnings last quarter?
Acorda Therapeutics Inc (NASDAQ:ACOR) posted its earnings results on Thursday, February, 15th. The biopharmaceutical company reported $0.61 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.88 by $0.27. The biopharmaceutical company earned $188.40 million during the quarter, compared to analyst estimates of $171.70 million. Acorda Therapeutics had a negative net margin of 37.97% and a negative return on equity of 4.88%. The business's quarterly revenue was up 34.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.05 earnings per share. View Acorda Therapeutics' Earnings History.
When will Acorda Therapeutics make its next earnings announcement?
Where is Acorda Therapeutics' stock going? Where will Acorda Therapeutics' stock price be in 2018?
13 analysts have issued 1-year price targets for Acorda Therapeutics' shares. Their forecasts range from $13.00 to $37.00. On average, they anticipate Acorda Therapeutics' share price to reach $21.83 in the next year. View Analyst Ratings for Acorda Therapeutics.
What are Wall Street analysts saying about Acorda Therapeutics stock?
Here are some recent quotes from research analysts about Acorda Therapeutics stock:
- 1. According to Zacks Investment Research, "Acorda reported mixed results in the fourth quarter of 2017 with earnings missing estimates while revenues beating the same. Presently, the company is working on strengthening its Parkinson’s pipeline by focusing on the late stage candidate Inbrija in its portfolio. The FDA accepted Inbrija’s new drug application in February 2018. The company’s share price has outperformed the industry so far this year. However, the company’s key multiple sclerosis drug Ampyra is expected to face generic competition from mid-2018 in the United States. Hence, Acorda’s dependence on Ampyra to draw major part of its revenues is concerning. However, the candidate received a refusal-to-file letter from the FDA in August last year. This delayed its commercial launch which was expected much earlier." (3/13/2018)
- 2. HC Wainwright analysts commented, "Ziopharm’s CAR-T Programs Make a Splash at ASH; Reiterate Buy Ziopharm’s 2nd-gen CAR-T shows promise in early study. We attended the 2017 Annual Meeting of the American Society of Hematology (ASH) over the last weekend, where Ziopharm presented interim results from the ongoing Phase 1 clinical study in patients with CD19 + leukemia or lymphoma treated with Ziopharm’s second generation CD19 + CAR-T therapy. Recall, Ziopharm’s second generation CAR-T cells were manufactured using the company’s proprietary Sleeping Beauty (SB) transposon platform which shortens the manufacturing process to two weeks compared to the typical 3-4 weeks for currently approved CAR-T therapies, such as Kymriah from Novartis (NVS; not rated) and Yescarta from Gilead (GILD; not rated). The results from the Phase 1 study show that treatment of patients with relapsed/refractory leukemia or lymphoma (n = 8) resulted in a 50% complete response rate after one month of therapy." (12/14/2017)
- 3. Cantor Fitzgerald analysts commented, "Not what ACOR stock needed. ACOR announced this morning that an increase in blood monitoring for agranulocytosis is being implemented for subjects in the Phase 3 trial of tozadenant in Parkinson’s disease (PD)." (11/15/2017)
- 4. Stifel Nicolaus analysts commented, "Alexion (ALXN) reported 2Q17 sales/earnings and provided a business update (PDF) to investors. The company had a strong 2Q17, reporting sales of $912M and non-GAAP EPS of $1.56, beating OPCO by 9% and 25% respectively. The strong beat was partially attributable to favorable one-offs in 1H17, with 2H17 expected to see weaker growth, which was well flagged by the company. The pipeline keeps moving along with a positive opinion for Soliris rMG in the EU in June and a PDUFA date of Oct. 23, 2017. We were particularly struck by new management’s ability to stabilize the business, provide transparency and the continuing strong fundamentals." (7/28/2017)
Who are some of Acorda Therapeutics' key competitors?
Some companies that are related to Acorda Therapeutics include Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), Aerie Pharmaceuticals (AERI), Portola Pharmaceuticals (PTLA), Myriad Genetics (MYGN), Corcept Therapeutics (CORT), Akcea Therapeutics (AKCA), Motif Bio (MTFB), Sangamo Therapeutics (SGMO), Esperion Therapeutics (ESPR), Acceleron Pharma (XLRN), USANA Health Sciences (USNA), Spectrum Pharmaceuticals (SPPI), Denali Therapeutics (DNLI), Cambrex (CBM), Clinigen Group (CLIGF), Aimmune Therapeutics (AIMT) and Editas Medicine (EDIT).
Who are Acorda Therapeutics' key executives?
Acorda Therapeutics' management team includes the folowing people:
- Ron Cohen, President,Chief Executive Officer, Director (Age 62)
- Richard P. Batycky Ph.D., Chief Technology Officer and Site Head (Age 49)
- David Lawrence, Chief Business Operations, Principal Accounting Officer (Age 59)
- Andrew R. Blight Ph.D., Chief Scientific Officer (Age 66)
- Jane Wasman J.D., President - International, General Counsel, Corporate Secretary (Age 61)
- Burkhard Blank M.D., Chief Medical Officer (Age 62)
- Andrew Hindman, Chief Business Development Officer (Age 44)
- Lauren M. Sabella, Chief Commercial Officer (Age 56)
- Barry E. Greene, Independent Director (Age 53)
- Peder K. Jensen M.D., Independent Director (Age 62)
Has Acorda Therapeutics been receiving favorable news coverage?
Headlines about ACOR stock have been trending somewhat positive on Monday, according to Accern. The research firm rates the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Acorda Therapeutics earned a news sentiment score of 0.12 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 44.94 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are Acorda Therapeutics' major shareholders?
Acorda Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include
SCOPIA CAPITAL MANAGEMENT LP
SCOPIA CAPITAL MANAGEMENT LP
(18.10%), Geode Capital Management LLC (0.88%), Spark Investment Management LLC (0.88%), Schwab Charles Investment Management Inc. (0.65%) and Bogle Investment Management L P DE (0.53%). Company insiders that own Acorda Therapeutics stock include Andrew A Hindman, Barry E Greene, Burkhard Blank, David Lawrence, Jane Wasman, Lorin Randall, Richard P Batycky, Ron Cohen, Scopia Capital Management Lp and Steven M Rauscher. View Institutional Ownership Trends for Acorda Therapeutics.
Which major investors are selling Acorda Therapeutics stock?
ACOR stock was sold by a variety of institutional investors in the last quarter, including Gotham Asset Management LLC, TIAA CREF Investment Management LLC, Spark Investment Management LLC, Two Sigma Advisers LP, Alambic Investment Management L.P., Guggenheim Capital LLC, Geode Capital Management LLC and Metropolitan Life Insurance Co. NY. Company insiders that have sold Acorda Therapeutics company stock in the last year include Andrew A Hindman, Barry E Greene, Burkhard Blank, David Lawrence and Lorin Randall. View Insider Buying and Selling for Acorda Therapeutics.
Which major investors are buying Acorda Therapeutics stock?
ACOR stock was bought by a variety of institutional investors in the last quarter, including Bogle Investment Management L P DE, Millennium Management LLC, Arizona State Retirement System, Sphera Funds Management LTD., Virtus Fund Advisers LLC, Alliancebernstein L.P., Acadian Asset Management LLC and MetLife Investment Advisors LLC. Company insiders that have bought Acorda Therapeutics stock in the last two years include Ron Cohen and Scopia Capital Management Lp. View Insider Buying and Selling for Acorda Therapeutics.
How do I buy shares of Acorda Therapeutics?
Shares of ACOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Acorda Therapeutics' stock price today?
One share of ACOR stock can currently be purchased for approximately $25.05.
How big of a company is Acorda Therapeutics?
Acorda Therapeutics has a market capitalization of $1.18 billion and generates $588.29 million in revenue each year. The biopharmaceutical company earns $-223,350,000.00 in net income (profit) each year or ($4.84) on an earnings per share basis. Acorda Therapeutics employs 484 workers across the globe.
How can I contact Acorda Therapeutics?
Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The biopharmaceutical company can be reached via phone at 914-347-4300.
MarketBeat Community Rating for Acorda Therapeutics (ACOR)MarketBeat's community ratings are surveys of what our community members think about Acorda Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Acorda Therapeutics (NASDAQ:ACOR) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Hold||Hold||Hold||Hold|
|Consensus Rating Score: ||2.15||2.15||2.00||2.22|
|Ratings Breakdown: ||1 Sell Rating(s)|
9 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
9 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|2 Sell Rating(s)|
10 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
7 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$21.83||$21.83||$20.77||$23.67|
|Price Target Upside: ||12.84% downside||13.01% downside||2.49% downside||21.06% upside|
Acorda Therapeutics (NASDAQ:ACOR) Consensus Price Target History
Acorda Therapeutics (NASDAQ:ACOR) Analyst Ratings History
(Data available from 3/19/2016 forward)
Acorda Therapeutics (NASDAQ:ACOR) Earnings History and Estimates Chart
Acorda Therapeutics (NASDAQ ACOR) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/15/2018||Q4 2017||$0.88||$0.61||$171.70 million||$188.40 million||View||N/A|
|10/31/2017||Q3 2017||$0.69||$0.43||$150.64 million||$141.07 million||View||N/A|
|7/27/2017||Q2 2017||$0.13||$0.29||$139.81 million||$139.40 million||View||N/A|
|4/27/2017||Q1 2017||($0.16)||($0.08)||$127.34 million||$119.39 million||View||N/A|
|2/14/2017||Q416||($0.18)||$0.05||$137.90 million||$140.63 million||View||Listen|
|10/27/2016||Q316||($0.26)||($0.04)||$134.01 million||$135.61 million||View||Listen|
|7/28/2016||Q216||$0.18||$0.07||$128.33 million||$127.45 million||View||Listen|
|4/28/2016||Q116||$0.08||$0.07||$115.36 million||$115.90 million||View||Listen|
|2/11/2016||Q415||$0.22||$0.28||$128.24 million||$130.90 million||View||Listen|
|10/22/2015||Q315||$0.15||$0.31||$115.52 million||$148.20 million||View||Listen|
|7/30/2015||Q215||($0.01)||$0.31||$110.84 million||$113.70 million||View||Listen|
|4/30/2015||Q115||$0.03||($0.02)||$100.20 million||$99.85 million||View||N/A|
|2/12/2015||Q414||$0.15||$0.33||$110.80 million||$117.90 million||View||N/A|
|10/30/2014||Q314||$0.04||$0.34||$94.70 million||$106.00 million||View||N/A|
|7/31/2014||Q214||$0.14||$0.24||$91.40 million||$97.13 million||View||N/A|
|5/6/2014||Q114||$0.04||$0.08||$81.30 million||$80.52 million||View||N/A|
|2/19/2014||Q413||$0.18||$0.32||$89.96 million||$92.59 million||View||N/A|
|10/31/2013||Q313||$0.13||$0.36||$90.01 million||$84.92 million||View||Listen|
|8/1/2013||Q2 2013||$0.09||$0.25||$82.57 million||$87.05 million||View||Listen|
|5/2/2013||Q1 2013||$0.20||$0.09||$80.77 million||$71.90 million||View||Listen|
|2/13/2013||Q4 2012||$0.15||$0.24||$78.90 million||$81.47 million||View||Listen|
|10/31/2012||Q312||$0.10||$0.38||$75.20 million||$77.44 million||View||N/A|
Acorda Therapeutics (NASDAQ:ACOR) Earnings Estimates
2018 EPS Consensus Estimate: ($0.62)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Acorda Therapeutics (NASDAQ:ACOR)
No dividend announcements for this company have been tracked by MarketBeat.com
Acorda Therapeutics (NASDAQ ACOR) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.90%
Acorda Therapeutics (NASDAQ ACOR) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|1/19/2018||David Lawrence||Insider||Sell||31,000||$27.58||$854,980.00||5,275|| |
|12/1/2017||Burkhard Blank||Insider||Sell||11,050||$20.53||$226,856.50||33,150|| |
|10/9/2017||David Lawrence||Insider||Sell||250||$25.40||$6,350.00|| |
|8/29/2017||Scopia Capital Management Lp||Major Shareholder||Buy||766,201||$19.23||$14,734,045.23|| |
|8/1/2017||Barry E Greene||Director||Sell||10,000||$21.57||$215,700.00||10,000|| |
|7/31/2017||Lorin Randall||Director||Sell||10,000||$21.66||$216,600.00||10,000|| |
|6/16/2017||Ron Cohen||Insider||Buy||20,000||$16.95||$339,000.00||511,648|| |
|5/15/2017||Andrew A Hindman||Insider||Sell||7,704||$15.75||$121,338.00||46,123|| |
|12/14/2016||Ron Cohen||Insider||Sell||40,172||$20.75||$833,569.00||519,860|| |
|10/21/2016||Richard P Batycky||Insider||Sell||2,063||$20.30||$41,878.90||45,916|| |
|10/7/2016||David Lawrence||Insider||Sell||250||$20.82||$5,205.00||8,952|| |
|10/3/2016||Jane Wasman||Insider||Sell||3,750||$20.78||$77,925.00||105,021|| |
|9/23/2016||Jane Wasman||Insider||Sell||500||$27.32||$13,660.00||109,271|| |
|6/22/2016||David Lawrence||Insider||Sell||500||$25.09||$12,545.00||9,702|| |
|6/8/2016||Steven M Rauscher||Director||Sell||1,086||$27.83||$30,223.38||1,086|| |
|5/13/2016||Andrew A Hindman||Insider||Sell||4,860||$26.11||$126,894.60||49,670|| |
|4/19/2016||Lorin Randall||Director||Sell||1,488||$28.68||$42,675.84||1,488|| |
|1/4/2016||Ian F. Smith||Director||Sell||13,231||$41.85||$553,717.35|| |
|12/23/2015||Jane Wasman||insider||Sell||10,751||$43.10||$463,368.10||100,124|| |
|12/22/2015||Lauren M. Sabella||insider||Sell||7,113||$42.04||$299,030.52||14,378|| |
|12/21/2015||Jane Wasman||Insider||Sell||817||$42.00||$34,314.00||108,579|| |
|12/18/2015||David Lawrence||insider||Sell||39,026||$40.63||$1,585,626.38||9,202|| |
|12/17/2015||Lauren M. Sabella||insider||Sell||14,229||$40.00||$569,160.00||14,378|| |
|12/1/2015||Enrique J Carrazana||Insider||Sell||7,218||$38.08||$274,861.44||32,148|| |
|12/1/2015||Ron Cohen||CEO||Sell||11,850||$38.08||$451,248.00||400,550|| |
|10/19/2015||Andrew Blight||insider||Sell||32,500||$30.87||$1,003,275.00||71,659|| |
|10/7/2015||Michael W. Rogers||CFO||Sell||5,700||$30.24||$172,368.00||41,677|| |
|10/5/2015||Jane Wasman||insider||Sell||3,750||$31.75||$119,062.50||98,097|| |
|10/5/2015||Ron Cohen||CEO||Sell||135,000||$28.03||$3,784,050.00||412,400|| |
|9/21/2015||Andrew Blight||insider||Sell||13,085||$31.30||$409,560.50||71,659|| |
|5/15/2015||Andrew A Hindman||Insider||Sell||4,779||$29.82||$142,509.78|| |
|1/12/2015||Enrique J Carrazana||Insider||Sell||97,993||$42.21||$4,136,284.53|| |
|12/18/2014||David Lawrence||Insider||Sell||27,109||$40.11||$1,087,341.99|| |
|12/18/2014||John P Kelley||Director||Sell||10,000||$40.00||$400,000.00|| |
|12/1/2014||David Lawrence||Insider||Sell||8,898||$35.60||$316,768.80|| |
|12/1/2014||Lauren M Sabella||VP||Sell||3,242||$35.58||$115,350.36|| |
|12/1/2014||Michael W Rogers||CFO||Sell||230||$35.58||$8,183.40|| |
|12/1/2014||Ron Cohen||CEO||Sell||34,394||$35.59||$1,224,082.46|| |
|10/7/2014||Michael W Rogers||CFO||Sell||5,700||$33.10||$188,670.00|| |
|10/3/2014||Jane Wasman||Insider||Sell||3,750||$34.13||$127,987.50|| |
|9/24/2014||Jane Wasman||Insider||Sell||14,923||$36.00||$537,228.00|| |
|8/27/2014||Jane Wasman||Insider||Sell||14,923||$33.00||$492,459.00|| |
|12/5/2013||Lauren Sabella||VP||Sell||8,797||$31.81||$279,832.57||12,403|| |
|12/2/2013||Enrique Carrazana||Insider||Sell||1,640||$33.56||$55,038.40||32,527|| |
|10/15/2013||Enrique J Carrazana||Insider||Sell||3,333||$32.38||$107,922.54|| |
|10/3/2013||Jane Wasman||Insider||Sell||3,750||$35.74||$134,025.00||105,459|| |
|8/20/2013||Ron Cohen||CEO||Sell||149,000||$34.10||$5,080,900.00||478,868|| |
|8/2/2013||John Kelley||Director||Sell||15,000||$38.00||$570,000.00|| |
|7/19/2013||Andrew Blight||Insider||Sell||19,296||$37.82||$729,774.72|| |
|6/10/2013||Ron Cohen||CEO||Sell||11,000||$34.15||$375,650.00|| |
|5/8/2013||Sandra Phd Panem||Director||Sell||10,000||$33.80||$338,000.00|| |
|12/4/2012||Lauren M Sabella||VP||Sell||4,364||$24.58||$107,267.12|| |
|12/3/2012||Andrew Blight||Insider||Sell||7,200||$24.20||$174,240.00|| |
|12/3/2012||David Lawrence||CFO||Sell||9,313||$24.21||$225,467.73|| |
|12/3/2012||Ron Cohen||CEO||Sell||16,407||$24.22||$397,377.54|| |
|11/13/2012||Sandra Phd Panem||Director||Sell||22,569||$24.12||$544,364.28|| |
Acorda Therapeutics (NASDAQ ACOR) News Headlines
Acorda Therapeutics (NASDAQ:ACOR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Acorda Therapeutics (NASDAQ:ACOR) Income Statement, Balance Sheet and Cash Flow Statement
Acorda Therapeutics (NASDAQ ACOR) Stock Chart for Monday, March, 19, 2018